Pfizer (PFE) – Analysts’ Recent Ratings Changes

Pfizer (NYSE: PFE) has recently received a number of price target changes and ratings updates:

• 6/23/2026 – Pfizer had its “outperform” rating reaffirmed by BMO Capital Markets.
• 6/21/2026 – Pfizer was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/13/2026 – Pfizer was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/9/2026 – Pfizer was upgraded by Royal Bank Of Canada from “underperform” to “sector perform”. They now have a $25.00 price target on the stock.
• 6/1/2026 – Pfizer had its “neutral” rating reaffirmed by Cantor Fitzgerald.
• 5/27/2026 – Pfizer had its “neutral” rating reaffirmed by UBS Group AG. They now have a $27.00 price target on the stock.
• 5/14/2026 – Pfizer had its “underperform” rating reaffirmed by Wolfe Research. They now have a $26.00 price target on the stock.
• 5/9/2026 – Pfizer was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/6/2026 – Pfizer was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 4/29/2026 – Pfizer had its price target raised by Citigroup Inc. from $26.00 to $27.00. They now have a “neutral” rating on the stock.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 7.3%. Pfizer’s payout ratio is 131.30%.

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.